833 results about "Lipoic acid" patented technology

This invention comprises administering to a human or animal in need of treatment an effective amount of an antioxidant lipoic acid derivative and/or pharmaceutically acceptable salts and solvates thereof for the treatment or prevention of pathological (inflammatory, proliferative and degenerative diseases, e.g. diabetes mellitus, atherosclerosis, Alzheimer's disease and chronic viral diseases) and non-pathological (e.g. skin aging and wrinkle formation) conditions caused by oxidative damage. Methods of synthesizing novel antioxidant lipoic acid derivatives and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are described. Another aspect of this invention is the use of these antioxidant compositions for the protection of skin from damage caused by ultraviolet radiation and dessication, and to provide improved skin feel by desquamating, cleansing and clarifying the skin. The compositions described in this invention increase cellular viability of epidermal cells, promote cytoprotection, and decrease the production of inflammatory mediators such as inflammatory cytokines in these cells. The antioxidant compositions are incorporated into sunscreen products, soap, moisturizing lotions, skin toners, and other skin care products.

The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and/or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex, dragons blood, mace, sage and red sandalwood with at least c) one compound capable of maximizing oxidative mitochondrial function preferably riboflavin or vitamin B₂ derivatives, FAD, FMN, 5-amino-6-(5′-phosphoribitylamino)uracil, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B₁, lipoic acid, biotin, vitamin B₆, vitamin B₁₂, folate, niacin, vitamin C and pantothenate and/or d) at least one lactic acid dehydrogenase inhibitor (preferably 2′,3,4′5,7-pentahydroxyflavone) and optionally f) an alkalizing agent (aloe vera, chlorella, wheat grass, sodium or potassium bicarbonate, potassium) g) an antiproliferative herb (speranskia or goldenseal) and h) a pharmaceutically acceptable carrier.

The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.

The invention describes a nutraceutical composition and method for preventing/treating cancer comprised of A) quinones (2,3-dimethoxy-5-methyl-1,4-benzoquinone, thymoquinone, tocopherolquinone) B) compounds capable of maximizing oxidative mitochondrial function preferably riboflavin, FAD, FMN, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B₁, lipoic acid, biotin, vitamin B₆, vitamin B₁₂, folate, B3, C and pantothenate C) lactic acid dehydrogenase inhibitors; 2′,3,4′5,7-pentahydroxyflavone, epigallocatechin gallate, quercetin, citric acid, rosemary, black walnut, clove, nutmeg, licorice root, coriander, cinnamon, ginger root, myrrh gum and green tea D) alkalizing agents: aloe vera, chlorella, wheat grass, apple cider vinegar, burdock root, kudzu root, alfalfa, barley grass, spirulina, parsley leaf, calcium, magnesium, potassium or bicarbonate salts E) potent tumoricidal herbs; gromwell root, wild yam, beth root, teasel root, balm of gilead bud, frankincense, bakuchi seed, dichroa root, kochia seed, kanta kari, sweet myrrh, galbanum, garcinia fruit, mace, white sage and tumoricial plant derived constituents: gambogic acid, shikonin, diosmin or boswellic acid F) an antiproliferative herb (speranskia or goldenseal) and G) a pharmaceutically acceptable carrier.

Described herein is a compound of Formula I, which is the metformin salt of the naturally occurring endogenous biological compound, (R)-(+) α lipoic acid, pharmaceutical compositions containing the compound of Formula I, and methods of treatment of diabetes or diabetic complications with the compound of Formula I.

A method for administering an antioxidant composition to humans according to their age and sex is disclosed wherein the method comprises administering to said humans a daily dose of a multiple antioxidant micronutrient composition comprising vitamin A (palmitate), beta carotene (from natural d. salina), vitamin C (calcium ascorbate), vitamin D-3 (cholecalciferol), natural source vitamin E including both d-alpha tocopheryl and d-alpha tocopheryl acid succinate, thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid (folacin), d-biotin, selenium (1-seleno methionine), chromium picolinate, zinc glycinate, calcium citrate, and magnesium citrate. For persons over the age of about 51, the composition preferably further comprises one or more of co-enzyme Q₁₀, N-acetyl cysteine, and alpha lipoic acid. Preferably, also, vitamin D is added for women over the age of about 36.

The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules.

Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.

A process is provided for producing lipoate esters from α-lipoic acid. The process comprises reacting α-lipoic acid with an alcohol and then adding a polymerization inhibitor such as L-cysteine.

Pharmaceutical formulations containing lipoic acid derivatives are made.

The invention relates to a cryopreservation liquid and a cryopreservation method for adipose tissue-derived mesenchymal stem cells ( ADSC). The cryopreservation liquid is composed of the following materials: 3 to 10 mg/ml of vitamine C, 2 to 8 mg/ml of vitamin E, 2 to 8 mg/ml of lipoic acid, 5 to 20 volume percent of human autoserum, and DMEM-LG culture medium in balancing amount. The cryopreservation liquid for ADSC does not contain animal serum and DMSO, and is composed of human autoserum, lipoic acid, vitamin E, vitamin C and other main materials. A cell cryopreserved with the cryopreservation liquid has the advantages of high palinesthesia rate, no impact on cell growth characteristic, and maintanience of stem cell pluripotency after palinesthesia.

Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.

The invention relates to SOD cell repair liquid and a preparation method thereof. The repair liquid contains superoxide dismutase (SOD), aloe juice, hyaluronic acid solution, alpha-lipoic acid and vitamin E; the weight ratio of the aloe juice, the hyaluronic acid solution, the alpha-lipoic acid to the vitamin E is 200-650 : 100-750 : 0.03-0.1 : 0.5-4; every 100g of the repair liquid contains 40000-4000000 activity unit of SOD; the preparation method is as follows: taking cactus stems and carrying out cell disruption, ultrafilter concentration and multistage precipitation and centrifugal separation process on the cactus stems to obtain crude enzyme supernatant; carrying out three-stage purification process and vacuum drying and grinding on the crude enzyme supernatant to obtain SOD freeze-dried powder; taking aloe plant leaves and carrying out degradation, decoloration, centrifugal separation process and filtration on the aloe plant leaves to obtain the aloe juice; blending the raw materials (components) according to the weight ratio for preparation to obtain the SOD cell repair liquid. The invention has the function of oxidation resistance, can alleviate physical fatigue and strengthen immunity of human body.

The invention relates to a supramolecular polymer based on lipoic acid or/and derivatives thereof and a preparation method thereof. The supramolecular polymer is mainly obtained by hot melting and mixing of the lipoic acid or/and derivatives thereof, a crosslinking agent and an iron source. The molar ratio of the lipoic acid or/and the derivatives thereof to the crosslinking agent to the iron source is 2:(0.1-1.5):(0.01-1); the lipoic acid or/and the derivatives thereof are selected from one of or a mixture of two or more compounds shown in formula I; and the crosslinking agent is a hydrocarbon compound containing carbon-carbon unsaturated bonds, and the iron source consists of an iron salt and an organic solvent capable of dissolving the iron salt. The supramolecular polymer provided bythe invention has the stretchability of more than 150 times and can repair itself at room temperature in an ultra-fast manner. In formula I (as described in the specification), R1 is hydrogen or C1-C4linear or branched alkyl, R2 is hydrogen or carboxyl, and n is an integer of 1-5.

The invention relates to a local anesthetic sustained-release preparation with phospholipid-mixed solvent-oil as a carrier, and a preparation method thereof. The sustained-release preparation is prepared from local anesthetic as an active ingredient and a mixture of phospholipid-mixed solvent-oil as a sustained-release drug delivery system, and selectively is prepared from an antioxidant, whereinthe local anesthetic is selected from one of bupivacaine or ropivacaine free base or a mixture thereof; the mixed solvent is a mixture of benzyl benzoate and one or two of benzyl alcohol, ethanol; theantioxidant is vitamin E acetate, lipoic acid and the like; in the phospholipid-mixed solvent-oil mixture, the content of phospholipid does not exceed 50%, the content of benzyl benzoate does not exceed 10%, and the rest is oil.